Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

SEATTLE GENETICS, INC. (SGEN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2018 01/12/2018 01/16/2018 01/17/2018 01/18/2018 Date
51.78(c) 52.36(c) 50.95(c) 52.56(c) 53.45(c) Last
1 432 366 926 614 950 172 1 862 587 1 026 770 Volume
-3.00% +1.12% -2.69% +3.16% +1.69% Change
More quotes
Financials ($)
Sales 2017 467 M
EBIT 2017 -217 M
Net income 2017 -131 M
Finance 2017 444 M
Yield 2017 -
Sales 2018 570 M
EBIT 2018 -176 M
Net income 2018 -168 M
Finance 2018 363 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 15,5x
EV / Sales2018 12,9x
Capitalization 7 693 M
More Financials
Company
Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer.Its product ADCETRIS, is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent,... 
More about the company
Surperformance© ratings of Seattle Genetics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SEATTLE GENETICS, INC.
01/18 SEATTLE GENETICS : to Host Conference Call and Webcast Discussion of Fourth Quar..
01/11 SEATTLE GENETICS : FDA Accepts Supplemental Biologics License Application and Gr..
01/08 SEATTLE GENETICS : Highlights Leadership in Expanding Field of Antibody-Drug Con..
01/03 SEATTLE GENETICS : FDA Accepts Supplemental Biologics License Application and Gr..
01/02 SEATTLE GENETICS : FDA Accepts Supplemental Biologics License Application and Gr..
2017 SEATTLE GENETICS : Takeda and Seattle Genetics to Present Positive Data from Pha..
2017 SEATTLE GENETICS : to Present at the J.P. Morgan Healthcare Conference
2017 SEATTLE GENETICS : and Bristol-Myers Squibb Highlight Interim Results from Phase..
2017 SEATTLE GENETICS : to Webcast Investor and Analyst Event at American Society of ..
2017 TAKEDA PHARMACEUTICAL : and Seattle Genetics to Present Positive Data from Phase..
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/18Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Qua.. 
01/18Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Qua.. 
01/18Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Qua.. 
01/18$SGEN Seattle Genetics to Host Conference Call and Webcast Discussion of Four.. 
01/17Didi's leader Jean Liu is sure to have the kind of trust and inside edge that.. 
More tweets
Qtime:116
News from SeekingAlpha
01/11 YOUR DAILY PHARMA SCOOP : Roche Highlights Pipeline, GenSight Gets Nod To Start ..
01/10 YOUR DAILY PHARMA SCOOP : Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides..
01/09 Seattle Genetics (SGEN) Presents At 36th Annual J.P. Morgan Healthcare Confer..
01/09 Analog Devices Is A Buy - Cramer's Lightning Round (1/8/18)
01/05 Goldman bullish on biopharma in 2018
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | SGEN | US8125781026 | 4-Traders
Technical analysis trends SEATTLE GENETICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 64,7 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Jonathan Drachman Chief Medical Officer, EVP-Research & Development
Vaughn B. Himes Chief Technology Officer
Robert J. Lechleider Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.-4.77%7 693
CELLTRION, INC.--.--%40 725
IQVIA HOLDINGS INC2.07%20 784
LONZA GROUP2.47%20 682
INCYTE CORPORATION-3.23%19 342
ALNYLAM PHARMACEUTICALS, INC.-1.90%12 256